The amino acid taurine is essential for the function of skeletal muscle and administration is proposed as a treatment for Duchenne Muscular Dystrophy (DMD).
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Introduction
Duchenne Muscular Dystrophy (DMD) is a lethal, X-chromosome linked muscle disease affecting about 1 in 3500-6000 boys worldwide [Reviewed in (Bushby et al., 2010 , Emery, 2002 ]. Mutations in the dystrophin gene result in either the absence or loss of functional dystrophin protein, with dystrophic skeletal muscles having an increased susceptibility to sarcolemma damage after muscle contraction, leading to myofibre necrosis, inflammation, regeneration and fibrosis (Grounds et al., 2008 , Kharraz et al., 2014 , Lapidos et al., 2004 , Petrof et al., 1993 . Repeated cycles of widespread myofibre necrosis and a progressive failure of regeneration lead to the loss of muscle mass and function in DMD boys with premature death often due to respiratory or cardiac failure [Reviewed in (Biggar, 2006 , Bushby, 2010 ].
Whilst the mechanism of necrosis in DMD and the mdx mouse model of the disease are not fully understood, inflammation, oxidative stress and disruptions in intracellular calcium homeostasis caused by sarcolemma instability are strongly implicated.
Various compounds that could potentially provide a therapeutic benefit have been tested, including antioxidants, anti-inflammatory drugs and calcium channel blockers.
One compound of interest is taurine (2-aminoethanesulfonic acid), a semi-essential amino acid that is found in many tissues and is especially important for the function of skeletal muscle (Bakker and Berg, 2004 , Hamilton et al., 2006 , Huxtable, 1992 , Warskulat et al., 2004 , Warskulat et al., 2007 . In skeletal muscle, taurine functions in the control of ion channel function, membrane stability and calcium homeostasis (Camerino et al., 2004) and taurine treatment of mdx mice improved grip strength, prevented exercise induced muscle weakness and restored calcium homeostasis (Cozzoli et al., 2011 , De Luca et al., 2003 . Taurine levels are decreased in mdx muscles before and during the onset of dystropathology (between three and six weeks), and the taurine deficiency diminishes as the disease pathology stabilised in adult mice (Griffin et al., 2001 , McIntosh et al., 1998 . Whilst the taurine content of DMD muscle has not been reported, the urinary excretion of taurine has been 4 reported to be increased in DMD boys (Engel et al., 1994) , suggesting perturbations in taurine homeostasis.
Whole body taurine homeostasis is regulated by a balance between multiple processes, including absorption from food in the intestine, reabsorption from the kidney, and endogenous synthesis from cysteine (Lambert et al., 2014) as depicted in Figure 1 . Maintenance of the intracellular taurine pool depends on active uptake from the extracellular space by the high affinity, low capacity, Na + dependent transporter, TauT (Ito et al., 2010) , and taurine is released from cells via volume insensitive and volume sensitive leak pathways (Lambert, 2014) . The liver is responsible for export of a substantial proportion of the taurine body pool into the plasma, and absorption of taurine from the diet in the liver by hepatocytes requires
TauT. Regulation of systemic taurine levels in the plasma occurs in the kidney by reabsorption of taurine in renal tubules. This requires TauT, which is inversely regulated in response to the plasma levels of taurine (Tappaz, 2004) . TauT also facilitates active transport of taurine into tissues such as muscle, along with the cotransport of sodium ions, which maintains a extraordinarily high concentration gradient (Huxtable, 1992) . Muscle function is dependent on adequate TauT. Deletion of exon 1 of the TauT gene results in a striking (98%) decrease in heart and skeletal muscle taurine levels, with severely impaired skeletal muscle function and exercise capacity (Warskulat, 2004) . TauT knockout mice also display severe abnormalities in muscle structure including decreased myofibre cross sectional area, myofilament fragmentation, and lipid droplets within the myofibre (Ito et al., 2008 , Ito, 2010 .
Another major cellular process that contributes to whole body taurine content is the synthesis of taurine from cysteine (summarised in Figure 1 ). Cysteine is a semiessential amino acid, which is present in the diet and can be synthesised from the amino acid methionine. Taurine synthesis is tightly regulated by cysteine availability, and in the liver this process serves as a method to dispose of toxic excess cysteine (Huxtable, 1992) . Cysteine is catabolised by the enzyme cysteine dioxygenase to cysteine sulfinate, which is decarboxylated to hypotaurine by the enzyme cysteine sulfinate decarboxylase, which is then oxidised to taurine (Huxtable, 1992) . While taurine formation is proposed to occur principally in the liver, other cells contain trace amounts of these enzymes and are thus also able to form taurine from cysteine, including the brain and skeletal muscle (Stipanuk, 2004) .
The cellular activity and expression of the enzymes cysteine deoxygenase and cysteine sulfinate decarboxylase are responsive to intracellular cysteine content, as well as dietary changes in protein and intake of sulfur amino acids (cysteine and methionine). Recently, we established that treatment of adult mdx mice with the cysteine precursor L-2-Oxothiazolidine-4-Carboxylate (OTC) led to an increase in the synthesis of taurine, resulting in a decreased dystropathology and reduced oxidative stress in the dystrophic muscle (Terrill et al., 2013) . These data suggest that taurine deficiency in mdx muscle may be due to insufficient synthesis of taurine.
A deficiency of taurine in mdx muscle appears to be correlated with the progression of the disease, which may indicate that dystrophy is perturbing taurine metabolism.
To evaluate this possibility, we investigated the multiple processes contributing to body taurine content (summarised in Figure 1) . We compared mdx and wildtype C57
(C57Bl/10ScSn) mice at three ages: pre-dystrophy (18 days), during active dystropathology (4 weeks) and when dystropathology has begun to stabilise to a lower level of active necrosis (6 weeks), and measured the content of taurine in liver, plasma and muscle. We examined the levels of TauT protein in liver, kidney and muscle in mdx and C57 mice at the three ages. The endogenous capacity to synthesise taurine in liver and muscle was evaluated by measuring the levels of the enzymes cysteine deoxygenase and cysteine sulfinate decarboxylase (which catalyze the synthesis of taurine from cysteine), and the intermediate metabolites cysteine sulfinate and hypotaurine. Since synthesis requires adequate cysteine availability, cysteine content was also measured in liver, plasma and muscle of all mice. The results showed perturbations in levels and metabolism of taurine in dystrophic tissue that varied with age in the growing mdx mice.
Methods
All reagents used were obtained from Sigma Aldrich (NSW, Australia) unless otherwise specified.
Animal procedures
All experiments were carried out on male dystrophic mdx (C57Bl/10ScSnmdx/mdx) and non-dystrophic control C57 (C57Bl/10ScSn) mice (the parental strain for mdx). 
Tissue collection
Mice were sacrificed at 18 days, 4 and 6 weeks of age by cervical dislocation while under terminal anesthesia (2%v/v Attane isoflurane, Bomac, Australia). Whole blood was collected via cardiac puncture using a 27.5 gauge tuberculin syringe, into a 1.5 ml tube and spun down immediately in a refrigerated centrifuged for 5 minutes (12000 g) and plasma removed, aliquoted and frozen at -80°C until analysis.
Quadriceps muscles, liver and kidney were collected and immediately snap frozen in liquid nitrogen for biochemical analyses.
HPLC analysis of metabolites
Taurine, cysteine, cysteine sulfinate and hypotaurine and in liver, plasma and quadriceps muscle was measured using reverse phase high performance liquid chromatography (HPLC) as previously described (Terrill, 2013) . Plasma samples were precipitated by addition of 10 times by weight of 5% trichloroacetic acid (TCA).
Frozen tissues were crushed using a mortar and pestle under liquid nitrogen and homogenized in 25 times 5% TCA. After centrifugation, supernatants were removed and stored at -80°C before analysis. Analytes were separated using HPLC with fluorescent detection, with pre-column derivitisation with o-phthalaldehyde (OPA) and 2-mercaptoethanol (2ME). OPA reacts rapidly with amino acids and sulfhydryl groups to yield intensely fluorescent derivatives, and 2ME, a reducing agent, prevents the OPA reagent from oxidising. Supernatants were mixed with iodoacetamide, dissolved in 5% TCA, to a final concentration of 25 mM. An internal standard, o-phospho-dlserine, dissolved in 5% TCA was added to a final concentration of 5 mM. pH was adjusted to 9 with the sodium borate. Samples were placed in the autosampler, which was maintained at 4°C. Samples were mixed on sample loop with the derivitising solution, containing 40 mM OPA and 160 mM 2ME in 100 mM sodium borate, pH 12, for 30 seconds before injection onto the column. Separation was achieved with a C18 column (5 µl, 4.6 x 150 mm, Phenomenex) using a Dionex Ultimate 3000 HPLC system. Mobile phase A consisted of 50 mM potassium phosphate buffer, methanol and tetrahydrofuran (94:3:3). Mobile phase B consisted of 90% Methanol, with a gradient increase in B from 0 to 25%. Fluorescence was set at 360 nm and 455 nm for excitation and emission respectively. Protein content of liver and muscle samples were quantified by solubilising the pellet in 0.5 M sodium hydroxide, before incubation at 80°C for 15 minutes. Once fully dissolved, protein concentrations of supernatants were quantified using a Bradford protein assay (BioRad, NSW, Australia).
Protein extraction and immunoblotting
Frozen tissues were crushed using a mortar and pestle under liquid nitrogen and homogenized in 1 ml ice-cold 1% NP40, 1 mM EDTA in phosphate buffered saline 
Statistics
Significant differences between groups were determined using one way ANOVA with post hoc tests and all data are presented as mean ± standard error of the mean (SEM). Significance was set at p < 0.05.
Results
Taurine content of C57 and mdx liver, plasma and muscle
Taurine content was measured (using HPLC) in wild type C57 and dystrophic mdx liver, plasma and quadriceps muscle at three ages: pre-dystropathology (18 days), during active dystropathology (4 weeks) and when dystropathology has begun to stabilise to a lower level of active necrosis (6 weeks).
In the liver of C57 mice the content of taurine declined dramatically from 18 days to 4 weeks, and remained low at 6 weeks ( Fig. 2) . Taurine content of 18 days mdx liver was strikingly lower (~50%) than 18 days C57 liver, but at 4 and 6 weeks, taurine levels were low and comparable in both strains (Fig. 2) .
In the plasma of C57 mice, the concentration of taurine declined from 18 days to 4 weeks and then increased at 6 weeks ( Fig. 2) . Taurine was significantly lower (~30%) in plasma of 18 day old mdx compared with C57 mice. Taurine concentration also declined in mdx plasma from 18 days to 4 weeks, and was not significantly different from c57 mice at 4 and 6 weeks ( Fig. 2 ).
In the quadriceps muscle of C57 mice, taurine content increased from 18 days to 6 weeks ( Fig. 2) . Taurine content was similar in mdx muscle at 18 days, but by 4 weeks mdx muscle had lower (~25%) taurine content than C57 muscle (Fig. 2 ). This deficiency was not evident at 6 weeks, with taurine content of 6 week mdx muscle also significantly higher than at 18 days (Fig. 2 ).
These data indicate taurine levels are perturbed in mdx mice. There is an apparent deficiency of taurine in growing mdx mice during active dystropathology at 4 weeks, with low plasma levels also evident at 18 days.
TauT expression in C57 and mdx liver, kidney and muscle
The maintenance of intracellular taurine pools in all tissues, including muscle, depends on uptake from the extracellular space by TauT, and we therefore measured the amount of TauT protein in liver, kidney and muscle of C57 and mdx mice, at the three ages.
In C57 liver, there were no significant changes in the amount of TauT protein from 18 days to 6 weeks. However, in mdx livers there was a striking increase (~200%) from 18 days to 4 weeks, with the mdx levels about 300% higher at 4 weeks compared with C57 liver (Fig. 3) . By 6 weeks, TauT levels in mdx liver had declined and were at levels comparable to C57 liver (Fig. 3 ).
In the C57 kidney, there was a striking increase (~1500%) in TauT from 18 days to 4 weeks, whereas TauT levels in in mdx kidney did not change significantly with age.
TauT protein levels were significantly higher (~200%) at 4 weeks in C57 compared with mdx kidney (Fig. 3) .
In C57 quadriceps muscle, TauT protein levels were similar at 18 days and 4 weeks, with a significant increase by 6 weeks (Fig. 3) . While levels of TauT protein in mdx muscle did not change significantly with age, levels were significantly lower for mdx compared with C57 muscles at 18 days and 6 weeks ( Fig. 3 ).
These data indicate TauT levels were perturbed in mdx mice. In muscle it is of note that TauT levels were depressed prior to active dystrophy. The perturbation extended beyond muscle with pertubations in TauT levels in liver and kidney during active dystropathology.
Cysteine content of C57 and mdx and liver, plasma and muscle
The synthesis of taurine requires an adequate supply of cysteine, therefore the content of cysteine in liver, plasma and muscle of mdx and C57 mice was measured at the three ages.
In C57 liver, the content of cysteine declined (~50%) from 18 days to 4 weeks, and remained low at 6 weeks (Fig. 4) . In contrast, cysteine did not change significantly in mdx liver with age (Fig. 4) . The key difference was that cysteine content of mdx liver at 18 days was about five times lower than C57 mice (Fig. 4) .
In C57 plasma, cysteine concentrations were similar at 18 days and 4 weeks, but decreased significantly by 6 weeks (Fig. 4) . Cysteine levels in mdx plasma were relatively unchanged with age (Fig 4) . The plasma levels of cysteine were lower (~30%) in mdx mice compared to C57 at both 18 days and 4 weeks, but levels were comparable at 6 weeks (Fig. 4) .
In C57 quadriceps muscle, the content of cysteine declined from 18 days to 6 weeks (Fig. 4) . In contrast, cysteine content did not change in mdx muscle from 18 days to 4
weeks, but was lower at 6 weeks (Fig. 4) . Note that at 18 days, the cysteine content of mdx muscle was about half that of C57 (Fig. 4) .
These data indicate cysteine levels were perturbed in mdx mice. Notably, prior to dystropathology in 18 day old mdx mice there was an apparent deficiency in cysteine content in liver and muscle, and a lower cysteine concentration in plasma.
3.4.
Taurine synthesis in C57 and mdx and liver and muscle.
The synthesis of taurine from cysteine begins with the catabolism of cysteine to cysteine sulfinate, by the enzyme cysteine deoxygenase, which is decarboxylated to hypotaurine by the enzyme cysteine sulfinate decarboxylase (Fig. 1) . We therefore measured protein levels of the enzymes cysteine deoxygenase and cysteine sulfinate decarboxylase, plus the intermediate metabolites cysteine sulfinate and hypotaurine in C57 and mdx and C57 livers and muscles, to assess whether the ability of mdx mice to synthesize taurine is compromised.
In livers of both strains, the expression of cysteine deoxygenase dropped dramatically (to ~4%) from 18 days to 4 weeks, and remained low at 6 weeks ( Fig.   5 ). The only significant difference in expression of cysteine deoxygenase was at 18 days where mdx liver was slightly higher than C57 (Fig. 5) . The product of cysteine deoxygenase activity, cysteine sulfinate, declined in C57 liver from 18 days to 6 weeks but did not change significantly in mdx livers (Fig. 5) . Levels of cysteine sulfinate decarboxylase protein increased in C57 liver from 18 days to 6 weeks ( Fig.   5 ). In contrast, the increase in cysteine sulfinate decarboxylase protein was delayed in mdx liver and did not increase until 6 weeks ( Fig. 5) . At 4 weeks, cysteine sulfinate decarboxylase expression in mdx liver was 3 times lower than in C57, and remained significantly lower at 6 weeks (Fig. 5) . Hypotaurine, the product of cysteine sulfinate decarboxylase activity, decreased in C57 liver from 18 days to 6 weeks ( Fig. 5) , however there was no significant change in hypotaurine content of mdx liver with age. Of note, hypotaurine content was significantly lower in 18 day mdx liver, compared to 18 day C57 liver (Fig. 5) .
We also measured content of these analytes in muscle, to assess the potential for de novo synthesis within the muscle. In marked contrast with C57 liver (Fig. 5) , cysteine deoxygenase expression in C57 quadriceps muscle did not change significantly with age ( Fig. 6) . While cysteine deoxygenase expression in mdx muscle decreased from 18 days to 4 weeks, it had recovered by 6 weeks (Fig. 6) . At 4 weeks, cysteine deoxygenase in mdx muscle was half that of C57 (Fig. 6 ). The pattern of cysteine sulfinate change with age was similar for C57 liver and muscle with a significant decrease only at 6 weeks ( Fig. 6 ) In mdx muscle, cysteine sulfinate content did not change with age (as was also seen for mdx liver), nor were then any significant differences with age matched C57 muscle.
Levels of the enzyme cysteine sulfinate decarboxylase declined in C57 muscle from 18 days to 4 weeks, and remained low at 6 weeks (Fig. 6 ). This is in direct contrast with the situation in liver where cysteine sulfinate decarboxylase increased with age (Fig. 5) . In mdx muscle, cysteine sulfinate decarboxylase displayed the same pattern, with no significant difference with age matched C57 muscle (Fig. 6 ). The content of hypotaurine declined in C57 muscle from 18 days to 4 weeks, and remained low at 6 weeks ( Fig. 6 ). Hypotaurine content in mdx muscle was not significantly different from C57 muscle at any age (Fig. 6 ).
Overall, these data indicate dystrophy may have affected taurine synthesis in the liver as indicated by the lower cysteine sulfinate decarboxylase levels during active dystropathology at 4 weeks and after dystropathology has stabilised at 6 weeks.
Interesting, the perturbation of cysteine sulfinate decarboxylase were not evident in dystrophic muscle, despite a significant decrease in cysteine deoxygenase at 4 weeks.
It should be noted, when comparing the content of these enzymes between liver and muscle, liver appears to have a much greater capacity for synthesis, with values for cysteine deoxygenase and cysteine sulfinate decarboxylase being 8 and 12 times higher respectively. Therefore the contribution of de novo synthesis of taurine in muscle to total taurine content is yet to be established.
Discussion
The key finding of this research is that in the mdx mouse, a dystrophin deficiency not only perturbs taurine metabolism in the muscle but also affects taurine metabolism in the liver and kidney. These disturbances occur both before and after the onset of dystropathology. Given that the key defect, absence of dystrophin, mainly affects muscle, perturbations of taurine metabolism in the liver and kidney presumably occur in response to metabolic disturbances in dystrophic myofibres.
In addition to establishing that taurine metabolism was perturbed in dystrophic muscle, novel data were generated on the development of taurine metabolism in normal (C57) growing juvenile mice. Our data indicate that between 18 days and 4 to 6 weeks, components of taurine metabolism undergo dramatic changes. The key findings are that at 18 days in C57 mice there are high levels of taurine in liver and plasma, elevated content of cysteine and cysteine deoxygenase in the liver, with low levels of the taurine transporter (TauT) in kidney. Most of these age-related changes can be explained by existing concepts about the regulation of taurine metabolism (table 1) .
In C57 liver, taurine content is more than 10 times higher at 18 days than at either 4 or 6 weeks, suggesting that in these very young mice (around the time of weaning)
there is either elevated taurine supply by the diet (milk), increased synthesis of taurine, or residual taurine derived from maternal circulation during gestation.
Taurine is the most abundant amino acid in mouse milk (Rassin et al., 1978) , and in newborn rats, the taurine content in milk rises dramatically from birth through to weaning (Huxtable and Lippincott, 1983) . However, in 20 day old rats (at time of weaning), only 13% of body taurine has come from milk, 4% is derived from the mother and 83% is synthesised de novo (Huxtable and Lippincott, 1983) .
The liver readily synthesises taurine when cysteine supply is abundant (Stipanuk, 2004) . The key enzyme cysteine deoxygenase responds rapidly to increases in the amount of dietary protein or sulfur amino acids, with increases in cysteine deoxygenase activity and expression (Bagley and Stipanuk, 1995, Stipanuk et al., 2002) . The activity and expression of cysteine sulfinate decarboxylase is not as highly responsive to changes in sulfur amino acid intake (Jerkins et al., 1998) , so cysteine deoxygenase activity is considered the major controlling factor in the synthesis of taurine from cysteine (Stipanuk, 2004) . Therefore, the elevated cysteine deoxygenase levels in livers of 18 day old C57 mice, relative to 4 and 6 week old C57 mice, is likely due to high liver cysteine content. High cysteine deoxygenase in liver would enhance taurine synthesis, and this would contribute to the high taurine content in liver at 18 days. Furthermore, increased taurine synthesis by the liver, combined with taurine availability from milk, are likely to account for the high taurine concentration in plasma of 18 day old C57 mice.
One potential consequence of increased taurine in plasma is decreased expression or activity of TauT in the kidney (Tappaz, 2004) . The taurine body pool is regulated by inverse regulation of TauT in response to the plasma levels of taurine, and increasing taurine plasma levels down-regulate TauT mRNA in the kidney (Matsell et al., 1997 , Tappaz, 2004 . The low TauT in kidneys of 18 day old C57 mice indicates a likely down-regulation in response to increased plasma taurine levels, resulting in increased excretion of taurine in urine. For C57 mice, from 18 days to 4 weeks, there was a drop in plasma taurine levels, and a dramatic increase in TauT expression in the kidney, indicating that as the taurine availability decreases, there is increased retention of taurine.
Our data indicate that taurine content in muscle, which increased from 18 days to 6 weeks of age was not responding to plasma taurine, which decreased over the In dystrophic mice, our data show that taurine content was lower in mdx muscle than C57 muscle at 4 weeks, during active dystropathology. Since taurine treatment improves mdx muscle pathology (Cozzoli, 2011 , De Luca, 2003 , this decline in taurine content may exacerbate the breakdown of dystrophic muscle. The cause of this low muscle taurine is unclear. A decline in taurine uptake does not appear to be causal as plasma levels of taurine and Taut content in muscle were similar to C57 levels at 4 weeks. One possibility is deficient taurine synthesis by mdx muscle, as cysteine deoxygenase was significantly lower than C57 muscle at 4 weeks, however, the overall contribution of de novo synthesis in muscle to taurine content is yet to be established.
A key finding is the evidence of perturbations in taurine metabolism that extended beyond the muscle of dystrophic mice. Future experimental research to assess the extent of this perturbation may be useful, for example to examine the cysteine and taurine content of tissues such as brain and heart, and expression of TauT in tissues such as the gut. The pathogenic pathway(s) causing the perturbation in taurine metabolism remain to be elucidated. One possibility is that in 4 week mdx mice, the presence of dystropathology could be a contributing factor. Inflammatory responses associated with dystropathology result in the release of cytokines which have the potential to affect tissues distal to the site of injury (Tidball, 2005) . However, taurine levels in liver and plasma are lower in 18 day old mdx mice relative to C57 mice. These perturbations in taurine metabolism are occurring when the mdx limb muscles are still intact, prior to the acute onset of dystropathology around 21 days. Another possibility is that these perturbations are a consequence of changes in metabolic demands of dystrophic muscles. Energy expenditure, muscle protein synthesis, and whole body protein turnover rates are considerably higher in mdx mice relative to age-matched controls (Radley-Crabb et al., 2014) . It is plausible that the increase in metabolic demand is responsible for the lower cysteine content is in liver, plasma and muscle of 18 day old mdx mice relative C57 mice. The liver readily synthesises taurine when cysteine supply is adequate, but when cysteine is lacking it is conserved for other functions (Stipanuk, 2004) . As a consequence, the decreased availability of cysteine would lead to decreased synthesis of taurine and a decrease in taurine content of liver and plasma.
In summary, we have established that dystrophy perturbs taurine metabolism in 
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